Scott E Eggener

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5147338/publications.pdf

Version: 2024-02-01

231 papers	13,184 citations	23544 58 h-index	24961 109 g-index
237 all docs	237 docs citations	237 times ranked	12149 citing authors

#	Article	IF	Citations
1	Should Grade Group 1 (GG1) be called cancer?. World Journal of Urology, 2022, 40, 15-19.	1.2	11
2	Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology, 2022, 302, 368-377.	3.6	14
3	Active Surveillance: Very Much â€œPreferredâ€•for Low-Risk Prostate Cancer. Journal of Urology, 2022, 207, 262-264.	0.2	3
4	Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. Journal of Urology, 2022, 207, 1236-1245.	0.2	1
5	Re: NCCN Prostate Cancer Guidelines Version 1.2022 â€“ September 10, 2021. European Urology, 2022, 81, 218.	0.9	2
6	Radical Prostatectomy Without Biopsy: Audacious, Imprudent, or Innovative?. European Urology, 2022, 82, 161-162.	0.9	1
7	Reply by Authors. Journal of Urology, 2022, , 101097JU0000000000000244302.	0.2	0
8	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World Journal of Urology, 2022, 40, 1505-1512.	1.2	12
9	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology, 2022, 82, 341-351.	0.9	32
10	Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. Journal of Clinical Oncology, 2022, 40, 3110-3114.	0.8	41
11	T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. European Radiology, 2021, 31, 325-332.	2.3	3
12	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	2.6	45
13	Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement. European Urology, 2021, 79, 552-553.	0.9	0
14	Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. European Urology, 2021, 79, 419-426.	0.9	36
15	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	2.6	67
16	Reply by Authors. Journal of Urology, 2021, 205, 779-779.	0.2	1
17	Editorial Comment. Journal of Urology, 2021, 206, 668-668.	0.2	0
18	Pathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy. Canadian Journal of Urology, 2021, 28, 10620-10624.	0.0	0

#	Article	IF	Citations
19	Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. European Urology Oncology, 2020, 3, 198-206.	2.6	9
20	Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 172-178.	2.0	11
21	Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. Journal of the National Cancer Institute, 2020, 112, 847-854.	3.0	23
22	Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics. Cancer, 2020, 126, 470-472.	2.0	2
23	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1474-1494.	0.8	141
24	Impact of Nonâ€“guideline-directed Care on Quality of Life in Testicular Cancer Survivors. European Urology Focus, 2020, 7, 1137-1142.	1.6	5
25	An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. JACC: Case Reports, 2020, 2, 2460-2464.	0.3	0
26	Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago. Preventive Medicine Reports, 2020, 20, 101174.	0.8	7
27	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
28	Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints. European Urology, 2020, 78, 161-162.	0.9	0
29	Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. Journal of Urology, 2020, 203, 706-712.	0.2	152
30	Ablation energies for focal treatment of prostate cancer. World Journal of Urology, 2019, 37, 409-418.	1.2	34
31	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. Future Oncology, 2019, 15, 1683-1695.	1.1	35
32	Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers. European Urology, 2019, 76, 610-611.	0.9	5
33	Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. European Urology, 2019, 76, 686-692.	0.9	18
34	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. European Urology, 2019, 76, 268-272.	0.9	28
35	Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer, 2019, 125, 2965-2974.	2.0	9
36	Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. American Journal of Roentgenology, 2019, 213, W66-W75.	1.0	14

#	Article	IF	Citations
37	Lymph node count impacts survival following postâ€chemotherapy retroperitoneal lymphadenectomy for nonâ€seminomatous testicular cancer: a populationâ€based analysis. BJU International, 2019, 124, 792-800.	1.3	12
38	International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy. Urology, 2019, 129, 132-138.	0.5	1
39	Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. , 2019, 7, 66.		63
40	Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010â€“2015. European Urology, 2019, 76, 252.	0.9	1
41	Diagnosis of non-neoplastic renal diseases in renal mass biopsies. Journal of Onco-Nephrology, 2019, 3, 49-52.	0.3	2
42	Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging. European Urology Oncology, 2019, 2, 257-264.	2.6	5
43	Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology, 2019, 123, 186-190.	0.5	13
44	Obscenity, Michael Jordan, and Measuring Outcomes: Explaining and Improving the Quality of Kidney Cancer Care. European Urology, 2019, 75, 635-636.	0.9	0
45	Evaluation of tumor coverage after MRâ€guided prostate focal laser ablation therapy. Medical Physics, 2019, 46, 800-810.	1.6	11
46	A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. Urology, 2019, 126, 76-82.	0.5	36
47	Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. American Journal of Roentgenology, 2019, 212, 351-356.	1.0	46
48	Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. Journal of Magnetic Resonance Imaging, 2019, 49, 1374-1380.	1.9	3
49	Editorial Comment. Journal of Urology, 2019, 201, 266-267.	0.2	1
50	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. Journal of Urology, 2019, 202, 272-281.	0.2	157
51	SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. Journal of Urology, 2019, 202, 952-958.	0.2	8
52	Reply by Authors. Journal of Urology, 2019, 202, 958-958.	0.2	0
53	Region-specific innate antiviral responses of the human epididymis. Molecular and Cellular Endocrinology, 2018, 473, 72-78.	1.6	13
54	Testicular Cancer. Medical Clinics of North America, 2018, 102, 251-264.	1.1	120

#	Article	IF	Citations
55	Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiologic Clinics of North America, 2018, 56, 187-196.	0.9	13
56	Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium. Investigative Radiology, 2018, 53, 609-615.	3.5	19
57	No Effect of Music on Anxiety and Pain During Transrectal Prostate Biopsies: A Randomized Trial. Urology, 2018, 117, 31-35.	0.5	19
58	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 378, 1767-1777.	13.9	2,036
59	Novel focal therapy treatment options for prostate cancer. Current Opinion in Urology, 2018, 28, 178-183.	0.9	7
60	Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment. European Urology, 2018, 73, 897-898.	0.9	1
61	Region-specific microRNA signatures in the human epididymis. Asian Journal of Andrology, 2018, 20, 539.	0.8	16
62	Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study. European Urology Oncology, 2018, 1, 501-506.	2.6	16
63	Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Current Opinion in Urology, 2018, 28, 461-468.	0.9	6
64	â€œReal-worldâ€•Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. European Urology, 2018, 74, 708-709.	0.9	0
65	Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later. Urology, 2018, 122, 16-18.	0.5	0
66	Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 85-93.	1.4	26
67	A novel transcriptional network for the androgen receptor in human epididymis epithelial cells. Molecular Human Reproduction, 2018, 24, 433-443.	1.3	19
68	MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. American Journal of Roentgenology, 2018, 211, 595-604.	1.0	16
69	Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget, 2018, 9, 21359-21365.	0.8	12
70	Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients. Reviews in Urology, 2018, 20, 63-68.	0.9	7
71	Active surveillance for prostate cancer. Translational Andrology and Urology, 2018, 7, 195-196.	0.6	0
72	Focal Therapy for Localized Prostate Cancer. Reviews in Urology, 2018, 20, 143-144.	0.9	0

#	Article	IF	Citations
73	Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. European Urology, 2017, 71, 476-482.	0.9	85
74	Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy. European Urology, 2017, 71, 515-516.	0.9	4
75	Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Stratification: A Systematic Review. European Urology Focus, 2017, 3, 487-497.	1.6	46
76	Influence of pathologist experience on positive surgical margins following radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 461.e1-461.e6.	0.8	8
77	Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017, 72, 238-249.	0.9	55
78	Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. European Urology, 2017, 72, 455-460.	0.9	28
79	Managing Cancer Relapse After Radical Prostatectomy. Urologic Clinics of North America, 2017, 44, 597-609.	0.8	1
80	African-American Prostate Cancer Disparities. Current Urology Reports, 2017, 18, 81.	1.0	77
81	Urology Residents' Experience and Attitude Toward Surgical Simulation: Presenting our 4-Year Experience With a Multi-institutional, Multi-modality Simulation Model. Urology, 2017, 109, 32-37.	0.5	8
82	Management trends for men with earlyâ€stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. Cancer, 2017, 123, 245-252.	2.0	24
83	Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdominal Radiology, 2017, 42, 346-349.	1.0	8
84	New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. European Urology, 2017, 71, 17-34.	0.9	232
85	Adherence to National Comprehensive Cancer NetworkÂ® Guidelines for Testicular Cancer. Journal of Urology, 2017, 197, 684-689.	0.2	52
86	Perspectives on International Urological Volunteerism: A Survey of IVUmed Resident Scholar Alumni. Urology Practice, 2017, 4, 176-182.	0.2	2
87	Risk of lymph node metastases in pathological gleason scoreâ‰¤6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 31.e1-31.e6.	0.8	14
88	Can Focal Treatment Replace Radical Treatment in Prostate Cancer? For Focal Therapy. European Urology Focus, 2017, 3, 522-523.	1.6	0
89	Nerve Bundle Hydrodissection and Sexual Function after Robot Prostatectomy. Journal of the Society of Laparoendoscopic Surgeons, 2017, 21, e2017.00068.	0.5	3
90	Prostate cancer detection following diagnosis of atypical small acinar proliferation. Canadian Journal of Urology, 2017, 24, 8714-8720.	0.0	10

#	Article	IF	Citations
91	Patient-Initiated Prostate Cancer Screening Among Older U.S. Men. Annals of Internal Medicine, 2016, 164, 702.	2.0	1
92	Corneal Abrasion in Hysterectomy and Prostatectomy. Survey of Anesthesiology, 2016, 60, 25.	0.1	0
93	Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study. BJU International, 2016, 117, 914-922.	1.3	8
94	Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Practical Radiation Oncology, 2016, 6, e179-e185.	1.1	9
95	Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of â€˜Richesâ€™?. European Urology, 2016, 70, 54-55.	0.9	9
96	Editorial Comment. Journal of Urology, 2016, 196, 1668-1669.	0.2	0
97	Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. Journal of Urology, 2016, 196, 1670-1675.	0.2	116
98	The Impact of Perioperative Aspirin on Bleeding Complications Following Robotic Partial Nephrectomy. Journal of Endourology, 2016, 30, 997-1003.	1.1	8
99	Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. American Journal of Surgical Pathology, 2016, 40, 1400-1406.	2.1	117
100	National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. Journal of Urology, 2016, 195, 1383-1389.	0.2	16
101	HNF1 regulates critical processes in the human epididymis epithelium. Molecular and Cellular Endocrinology, 2016, 425, 94-102.	1.6	16
102	The challenging landscape of medical device approval in localized prostate cancer. Nature Reviews Urology, 2016, 13, 91-98.	1.9	5
103	Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World Journal of Urology, 2016, 34, 687-693.	1.2	24
104	Expression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions. Molecular Human Reproduction, 2016, 22, 69-82.	1.3	64
105	The impact of days off between cases on perioperative outcomes for robotic-assisted laparoscopic prostatectomy. World Journal of Urology, 2016, 34, 269-274.	1.2	8
106	MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE. Journal of Urology, 2015, 193, .	0.2	1
107	Known Knowns, Known Unknowns, and Unknown Unknowns of High-intensity Focused Ultrasound for Prostate Cancer. European Urology Focus, 2015, 1, 171-172.	1.6	0
108	Corneal Abrasion in Hysterectomy and Prostatectomy. Anesthesiology, 2015, 122, 994-1001.	1.3	17

#	Article	IF	Citations
109	Management of Low-Stage Testicular Seminoma. Urologic Clinics of North America, 2015, 42, 287-298.	0.8	8
110	Updated Survey of Social Media Use by Members of the American Urological Association. Urology Practice, 2015, 2, 138-143.	0.2	14
111	Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology, 2015, 86, 777-782.	0.5	26
112	Characterization of primary cultures of adult human epididymis epithelial cells. Fertility and Sterility, 2015, 103, 647-654.e1.	0.5	25
113	Population Based Analysis of Incidence and Predictors of Open Conversion during Minimally Invasive Radical Prostatectomy. Journal of Urology, 2015, 193, 826-831.	0.2	12
114	How active should active surveillance be?. BJU International, 2015, 115, 176-177.	1.3	1
115	Focal Therapy: Patients, Interventions, and Outcomesâ€"A Report from a Consensus Meeting. European Urology, 2015, 67, 771-777.	0.9	206
116	Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes. World Journal of Urology, 2015, 33, 1689-1694.	1.2	13
117	Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World Journal of Urology, 2015, 33, 623-631.	1.2	131
118	National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigenâ€"Based Screening. Journal of Clinical Oncology, 2015, 33, 2416-2423.	0.8	184
119	News from Clinical Research Office of the Endourological Society (CROES). Journal of Endourology, 2015, 29, 495-497.	1.1	4
120	Genomic Predictors of Outcome in Prostate Cancer. European Urology, 2015, 68, 1033-1044.	0.9	166
121	Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 164.e11-164.e17.	0.8	26
122	Gleason 6 Prostate Cancer: Translating Biology into Population Health. Journal of Urology, 2015, 194, 626-634.	0.2	75
123	Prostate Cancer Screening. JAMA - Journal of the American Medical Association, 2015, 314, 825.	3.8	27
124	Giant Multilocular Cystadenoma of the Prostate:AIRP Best Cases in Radiologic-Pathologic Correlation. Radiographics, 2015, 35, 1051-1055.	1.4	9
125	National Trends in the Management of Low and Intermediate Risk Prostate Cancer in the United States. Journal of Urology, 2015, 193, 95-102.	0.2	84
126	Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 69.e29-69.e34.	0.8	8

#	Article	IF	Citations
127	Impact of warm versus cold ischemia on renal function following partial nephrectomy. World Journal of Urology, 2015, 33, 351-357.	1.2	15
128	Active surveillance monitoring: the role of novel biomarkers and imaging. Asian Journal of Andrology, 2015, 17, 882.	0.8	4
129	Indications for adrenalectomy during radical nephrectomy for renal cancer. Arab Journal of Urology Arab Association of Urology, 2014, 12, 304-308.	0.7	7
130	Validation of Quantitative Analysis of Multiparametric Prostate MR Images for Prostate Cancer Detection and Aggressiveness Assessment: A Cross-Imager Study. Radiology, 2014, 271, 461-471.	3.6	72
131	Health technology assessment in evolution â€“ focal therapy in localised prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 1359-1367.	1.1	7
132	Use of social media in urology: data from the <scp>A</scp>merican <scp>U</scp>rological <scp>A</scp>ssociation (<scp>AUA</scp>). BJU International, 2014, 113, 993-998.	1.3	135
133	The Impact of Body Mass Index on Renal Functional Outcomes Following Minimally Invasive Partial Nephrectomy. Journal of Endourology, 2014, 28, 1338-1344.	1.1	10
134	Elastographic search for the (highâ€grade) tree in the (prostatic) forest. BJU International, 2014, 113, 514-515.	1.3	0
135	Preoperative Nuclear Renal Scan Underestimates Renal Function After Radical Nephrectomy. Urology, 2014, 84, 1402-1407.	0.5	13
136	National trends in prostate cancer screening among older American men with limited 9â€year life expectancies: Evidence of an increased need for shared decision making. Cancer, 2014, 120, 1491-1498.	2.0	64
137	Revisiting the central gland anatomy via MRI: Does the central gland extend below the level of verumontanum?. Journal of Magnetic Resonance Imaging, 2014, 39, 167-171.	1.9	6
138	Laser ablation as focal therapy for prostate cancer. Current Opinion in Urology, 2014, 24, 236-240.	0.9	42
139	Effect of Depression on Diagnosis, Treatment, and Mortality of Men With Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 2471-2478.	0.8	115
140	Commentary on: â€œLong-term functional outcomes after treatment for localized prostate cancer.â€• Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 513-514.	0.8	12
141	Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design. European Urology, 2014, 65, 1078-1083.	0.9	180
142	Dynamic Contrast-enhanced MR Imaging Features of the Normal Central Zone of the Prostate. Academic Radiology, 2014, 21, 569-577.	1.3	23
143	Apparent Diffusion Coefficient for Prostate Cancer Imaging: Impact of b Values. American Journal of Roentgenology, 2014, 202, W247-W253.	1.0	51
144	Do Margins Matter? The Influence of Positive Surgical Margins on Prostate Cancerâ€“Specific Mortality. European Urology, 2014, 65, 675-680.	0.9	77

#	Article	IF	Citations
145	The Volume of Nonneoplastic Parenchyma in a Minimally Invasive Partial Nephrectomy Specimen: Predictive Factors and Impact on Renal Function. Journal of Endourology, 2014, 28, 196-200.	1.1	22
146	Commentary on â€œIs repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare.â€•Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 935-936.	0.8	3
147	Commentary on â€œAfrican American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: Should active surveillance still be an option for them?â€•Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM, Johns Hopkins University, Baltimore, MD.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 936.	0.8	1
148	Editorial Comment. Journal of Urology, 2014, 192, 81-81.	0.2	0
149	SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer. Cancer Cell, 2014, 25, 455-468.	7.7	154
150	Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance. European Urology, 2014, 66, 611-612.	0.9	25
151	The Role of Robot-assisted Radical Prostatectomy and Pelvic Lymph Node Dissection in the Management of High-risk Prostate Cancer: A Systematic Review. European Urology, 2014, 65, 918-927.	0.9	127
152	Short (â‰¤1â€‰mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU International, 2013, 111, 559-563.	1.3	22
153	Critical Evaluation of Modified Templates and Current Trends in Retroperitoneal Lymph Node Dissection. Current Urology Reports, 2013, 14, 511-517.	1.0	30
154	Empiric antibiotics for an elevated prostateâ€specific antigen (<scp>PSA</scp>) level: a randomised, prospective, controlled multiâ€institutional trial. BJU International, 2013, 112, 925-929.	1.3	22
155	Re: Do Adenocarcinomas of the Prostate with Gleason Score (GS) â‰¤6 Have the Potential to Metastasize to Lymph Nodes?. European Urology, 2013, 63, 960.	0.9	1
156	Prostate Volumes Derived From MRI and Volume-Adjusted Serum Prostate-Specific Antigen: Correlation With Gleason Score of Prostate Cancer. American Journal of Roentgenology, 2013, 201, 1041-1048.	1.0	31
157	Development and multiâ€institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer, 2013, 119, 3992-4002.	2.0	66
158	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. European Urology, 2013, 64, 544-552.	0.9	383
159	Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. Practical Radiation Oncology, 2013, 3, 138-144.	1.1	19
160	Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 904-908.	0.8	80
161	MR Imagingâ€“guided Focal Laser Ablation for Prostate Cancer: Phase I Trial. Radiology, 2013, 267, 932-940.	3.6	178
162	Quantitative Analysis of Multiparametric Prostate MR Images: Differentiation between Prostate Cancer and Normal Tissue and Correlation with Gleason Scoreâ€”A Computer-aided Diagnosis Development Study. Radiology, 2013, 267, 787-796.	3.6	229

#	Article	IF	Citations
163	Seminal Vesicle Invasion in Prostate Cancer: Evaluation by Using Multiparametric Endorectal MR Imaging. Radiology, 2013, 267, 797-806.	3.6	90
164	Imaging-guided Prostate Biopsy: Conventional and Emerging Techniques. Radiographics, 2012, 32, 819-837.	1.4	77
165	High-Grade Ureteroscopic Biopsy Is Associated with Advanced Pathology of Upper-Tract Urothelial Carcinoma Tumors at Definitive Surgical Resection. Journal of Endourology, 2012, 26, 398-402.	1.1	75
166	2008 US Preventive Services Task Force Recommendations and Prostate Cancer Screening Rates. JAMA - Journal of the American Medical Association, 2012, 307, 1692.	3.8	50
167	Environmental toxicology of testicular cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 212-215.	0.8	16
168	Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU International, 2012, 110, 942-948.	1.3	77
169	Re: Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?. Canadian Journal of Urology, 2012, 19, 6292.	0.0	0
170	Diffusion-Weighted and Dynamic Contrast-Enhanced MRI of Prostate Cancer: Correlation of Quantitative MR Parameters With Gleason Score and Tumor Angiogenesis. American Journal of Roentgenology, 2011, 197, 1382-1390.	1.0	221
171	Chronic Kidney Disease Before and After Partial Nephrectomy. Journal of Urology, 2011, 185, 43-48.	0.2	105
172	Warm ischemia less than 30 minutes is not necessarily safe during partial nephrectomy: Every minute matters. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 826-828.	0.8	58
173	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. Journal of Urology, 2011, 185, 869-875.	0.2	574
174	Prostate Cancer. Scientific World Journal, The, 2011, 11, 749-750.	0.8	5
175	Urinary cytology has a poor performance for predicting invasive or highâ€grade upperâ€tract urothelial carcinoma. BJU International, 2011, 108, 701-705.	1.3	195
176	Global Trends in Testicular Cancer Incidence and Mortality. European Urology, 2011, 60, 374-379.	0.9	134
177	Highâ€resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: Validation of a technique. Journal of Magnetic Resonance Imaging, 2011, 34, 956-961.	1.9	16
178	Clinical and Histologic Predictors of Renal Function Decline After Laparoscopic Partial Nephrectomy. Journal of Endourology, 2011, 25, 1435-1441.	1.1	20
179	Gleason 6 Prostate Cancer in One or Two Biopsy Cores Can Harbor More Aggressive Disease. Journal of Endourology, 2011, 25, 699-703.	1.1	8
180	Editorial Comment for Seideman et al.. Journal of Endourology, 2011, 25, 1247-1248.	1.1	3

#	Article	IF	Citations
181	Population-Based Patterns and Predictors of Prostate-Specific Antigen Screening Among Older Men in the United States. Journal of Clinical Oncology, 2011, 29, 1736-1743.	0.8	100
182	Local staging of prostate cancer with MRI. Diagnostic and Interventional Radiology, 2011, 18, 365-73.	0.7	29
183	Focal therapy for clinically localized prostate cancer. Archivos Espanoles De Urologia, 2011, 64, 815-22.	0.1	2
184	Editorial Comment on: Positive Surgical Margin Appears To Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery. European Urology, 2010, 57, 472.	0.9	6
185	Focal Therapy for Prostate Cancer: Possibilities and Limitations. European Urology, 2010, 58, 57-64.	0.9	95
186	Laparoscopic Partial Nephrectomy: A Single-center Evolving Experience. Urology, 2010, 75, 282-287.	0.5	27
187	The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. Urology, 2010, 75, 1431-1435.	0.5	47
188	Knotless Closure of the Collecting System and Renal Parenchyma with a Novel Barbed Suture During Laparoscopic Porcine Partial Nephrectomy. Journal of Endourology, 2009, 23, 1157-1160.	1.1	48
189	Editorial Comment on: Reducing Laparoscopic Radical Prostatectomy False-Positive Margin Rates Using Cyanoacrylate Tissue Glue. European Urology, 2009, 56, 658.	0.9	0
190	Editorial Comment on: Preservation of Lateral Prostatic Fascia is Associated with Urine Continence after Robotic-Assisted Prostatectomy. European Urology, 2009, 55, 900-901.	0.9	0
191	Editorial Comment on: Pharmacological Approaches to Reducing the Risk of Prostate Cancer. European Urology, 2009, 55, 1073-1074.	0.9	0
192	Editorial Comment on: Perioperative Morbidity of Laparoscopic Cryoablation of Small Renal Masses with Ultrathin Probes: A European Multicentre Experience. European Urology, 2009, 56, 361-362.	0.9	0
193	Comparison of models to predict clinical failure after radical prostatectomy. Cancer, 2009, 115, 303-310.	2.0	17
194	The clinical diversity of postchemotherapy germ cell teratoma. Cancer, 2009, 115, 1138-1141.	2.0	0
195	The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World Journal of Urology, 2009, 27, 477-483.	1.2	12
196	Retroperitoneal lymph node dissection: reassessment of modified templates. BJU International, 2009, 104, 1369-1375.	1.3	29
197	Robotic Radical Prostatectomy in Overweight and Obese Patients: Oncological and Validated-Functional Outcomes. Urology, 2009, 73, 316-322.	0.5	163
198	A Multi-Institutional Evaluation of Active Surveillance for Low Risk Prostate Cancer. Journal of Urology, 2009, 181, 1635-1641.	0.2	121

#	Article	IF	Citations
199	Suppressive Roles of Calreticulin in Prostate Cancer Growth and Metastasis. American Journal of Pathology, 2009, 175, 882-890.	1.9	47
200	Patient selection for focal therapy of localized prostate cancer. Current Opinion in Urology, 2009, 19, 268-273.	0.9	28
201	Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer, 2008, 113, 84-96.	2.0	85
202	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. Cancer Cell, 2008, 13, 519-528.	7.7	303
203	Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical Prostatectomy. European Urology, 2008, 53, 950-959.	0.9	174
204	Positive Surgical Margins at Partial Nephrectomy: Predictors and Oncological Outcomes. Journal of Urology, 2008, 179, 2158-2163.	0.2	260
205	Pathological Upgrading and Up Staging With Immediate Repeat Biopsy in Patients Eligible for Active Surveillance. Journal of Urology, 2008, 180, 1964-1968.	0.2	247
206	Relationship of Prostate-Specific Antigen Velocity to Histologic Findings in a Prostate Cancer Screening Program. Urology, 2008, 71, 1016-1019.	0.5	36
207	A Single Microfocus (5% or Less) of Gleason 6 Prostate Cancer at Biopsyâ€"Can We Predict Adverse Pathological Outcomes?. Journal of Urology, 2008, 180, 2436-2440.	0.2	26
208	Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. Journal of Clinical Oncology, 2008, 26, 5524-5529.	0.8	107
209	Focal Treatment of Prostate Cancer with Vascular-Targeted Photodynamic Therapy. Scientific World Journal, The, 2008, 8, 963-973.	0.8	26
210	Association of Cysteine-Rich Secretory Protein 3 and Î²-Microseminoprotein with Outcome after Radical Prostatectomy. Clinical Cancer Research, 2007, 13, 4130-4138.	3.2	76
211	Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. Journal of Clinical Oncology, 2007, 25, 4365-4369.	0.8	132
212	Radical Prostatectomy Shortly After Prostate Biopsy Does Not Affect Operative Difficulty or Efficacy. Urology, 2007, 69, 1128-1133.	0.5	27
213	Expression, Function of the Human Androgen-Responsive Gene AD11 in Prostate Cancer. Neoplasia, 2007, 9, 643-651.	2.3	35
214	Focal Therapy for Localized Prostate Cancer: A Critical Appraisal of Rationale and Modalities. Journal of Urology, 2007, 178, 2260-2267.	0.2	317
215	Incidence of Disease Outside Modified Retroperitoneal Lymph Node Dissection Templates in Clinical Stage I or IIA Nonseminomatous Germ Cell Testicular Cancer. Journal of Urology, 2007, 177, 937-943.	0.2	97
216	Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer, 2007, 109, 528-535.	2.0	73

#	Article	IF	Citations
217	The Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy. European Urology, 2007, 51, 940-948.	0.9	51
218	Editorial comment on: Methods of calculating prostate-specific antigen velocity. European Urology, 2007, 52, 1050-1.	0.9	0
219	Temporary Renal Ischemia During Nephron Sparing Surgery is Associated With Short-Term but Not Long-Term Impairment in Renal Function. Journal of Urology, 2006, 176, 1339-1343.	0.2	89
220	Prediagnosis Prostate Specific Antigen Velocity is Associated With Risk of Prostate Cancer Progression Following Brachytherapy and External Beam Radiation Therapy. Journal of Urology, 2006, 176, 1399-1403.	0.2	18
221	Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology, 2006, 68, 988-992.	0.5	24
222	Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: Early results. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 465-471.	0.8	17
223	Enhancement of intermittent androgen ablation by â€œoff-cycleâ€•maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate, 2006, 66, 495-502.	1.2	32
224	Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence. Journal of Clinical Oncology, 2006, 24, 3101-3106.	0.8	251
225	719: Renal Cell Carcinoma Recurrence Following Nephrectomy for Localized Disease: Predicting Survival from Time of Recurrence. Journal of Urology, 2006, 175, 233-233.	0.2	0
226	Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer. Clinical Cancer Research, 2005, 11, 4905-4911.	3.2	63
227	Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology, 2005, 66, 156-160.	0.5	50
228	Urolithiasis associated with topiramate. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2004, 30, 29-31.	0.7	6
229	Long-term survival after â€œdrop metastasesâ€•of renal cell carcinoma to the bladder. Urology, 2002, 60, 697.	0.5	23
230	Anatomy of the Rectourethralis Muscle. European Urology, 2002, 41, 94-100.	0.9	38
231	Juxtaglomerular apparatus tumor: a rare, surgically correctable cause of hypertension. Reviews in Urology, 2002, 4, 192-5.	0.9	11